Skip to main content

Skip to Investors Navigation

Pipeline

VMT-α-NET

Overview

VMT-α-NET is a clinical-stage radiopharmaceutical therapy for diagnosing and treating somatostatin receptor subtype 2 (SSTR2)-expressing neuroendocrine tumors (NETs). This radiopharmaceutical can be radiolabeled with Pb-203 for SPECT imaging and Pb-212 for alpha particle therapy.

203Pb SPECT Imaging Reveals Favorable VMT-α-NET Properties1

Rapid Tumor Targeting and Renal Clearance
High Tumor Retention
1Muller et al., Clin. Nucl. Med. 2023
  • Tumors visible within 1 hour indicates rapid binding to SSTR2 target
  • High intensity above background implies excellent therapeutic window
  • Unbound drug in bladder within 1 hour for excretion
  • Low renal retention due to neutral charge on proprietary Pb-specific chelator

Development

  • Therapeutic dose-finding trial in PRRT naïve setting currently recruiting throughout the US - https://clinicaltrials.gov/study/NCT05636618
  • Initiated therapy (2022) investigator led study in India – data on 13 patients presented at SNMMI in June 2024
  • Fast Track Designation for SSTR2+ NETs regardless of prior treatment response received 29th September 2022
  • US Phase 1 study in PRRT refractory patients recruiting at the University of Iowa
  • VMT-α-NET will potentially expand into this population as well as PRRT naïve patients